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Abstract
Tumor necrosis factor-receptor associated periodic syndrome (TRAPS) is a rare autosomal dominant autoinflammatory
disorder characterized by recurrent episodes of long-lasting fever and inflammation in different regions of the body, such as
the musculo-skeletal system, skin, gastrointestinal tract, serosal membranes and eye. Our aims were to evaluate circulating
microRNAs (miRNAs) levels in patients with TRAPS, in comparison to controls without inflammatory diseases, and to
correlate their levels with parameters of disease activity and/or disease severity. Expression levels of circulating miRNAs
were measured by Agilent microarrays in 29 serum samples from 15 TRAPS patients carrying mutations known to be
associated with high disease penetrance and from 8 controls without inflammatory diseases. Differentially expressed and
clinically relevant miRNAs were detected using GeneSpring GX software. We identified a 6 miRNAs signature able to
discriminate TRAPS from controls. Moreover, 4 miRNAs were differentially expressed between patients treated with the
interleukin (IL)-1 receptor antagonist, anakinra, and untreated patients. Of these, miR-92a-3p and miR-150-3p expression
was found to be significantly reduced in untreated patients, while their expression levels were similar to controls in samples
obtained during anakinra treatment. MiR-92b levels were inversely correlated with the number of fever attacks/year during
the 1st year from the index attack of TRAPS, while miR-377-5p levels were positively correlated with serum amyloid A (SAA)
circulating levels. Our data suggest that serum miRNA levels show a baseline pattern in TRAPS, and may serve as potential
markers of response to therapeutic intervention.
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Introduction
Tumor necrosis factor-receptor associated periodic syndrome
(TRAPS) is the most common autosomal dominant autoinflam-
matory disorder and is caused by mutations in the TNFRSF1A
gene (12p13) encoding the 55-kD receptor for tumor necrosis
factor-a (TNF-a) (TNFRSF1A) [1]. TRAPS is characterized by
recurrent fever attacks lasting typically from 1 to 3 weeks; in
addition to fever, common clinical features include mainly
periorbital oedema, conjunctivitis, a migratory erythematous skin
rash with underlying fasciitis and myalgia, and arthralgia and/or
arthritis [2], [3]; serosal inflammation is also common, usually but
not only in the form of polyserositis [4–8]. Mean age at disease
onset is around 3 years. Nevertheless TRAPS is the most variable
and multiform entity amongst autoinflammatory diseases both in
terms of age at disease onset and clinical manifestations [2–4], [9].
This heterogeneity is probably related to the wide spectrum of
known TNFRSF1A mutations [10]. TRAPS mutations can be
distinguished into high-penetrance variants and low-penetrance
variants: the former are mostly missense substitutions, mainly
affecting the highly conserved cysteine residues of the extracellular
cysteine-rich domains involved in disulfide bond formation and in
the folding of the extracellular portion of TNFRSF1A [2], [3].
These mutations are associated with an earlier disease onset and
with a more severe phenotype; in fact patients may experience a
higher number of fever episodes and a greater severity of attacks
[11]. These subjects also have a greater risk of developing AA
amyloidosis, the most troublesome TRAPS complication [2], [3],
[12]. On the contrary low-penetrance variants seem to be
associated with a milder phenotype, a later disease onset and a
lower risk of amyloidosis [3–9], [13].
The identification of TNFRSF1A mutations as the genetic cause
of TRAPS raised the possibility that blocking TNF - even though
TNF is not increased in most patients –could potentially represent
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a tailored therapeutic strategy, opening the way to new treatment
opportunities for this complex disease [14]. Etanercept has been
shown to control flares and inflammation in short case-series of
patients of different ages with fully penetrant TRAPS phenotypes
and in a prospective, open-label study [15], in which it proved to
decrease the frequency of the attacks and the disease severity [16–
18]. However, loss of response to etanercept over time as well as
etanercept-resistant patients have also been observed, suggesting a
non-specific action of etanercept in TRAPS [3], [19], [20].
Evidence of deregulated secretion of interleukin (IL)-1b recently
supported IL-1 inhibition as a target therapy for TRAPS and IL-1
inhibitors, such as the human IgG1 anti-IL-1b monoclonal
antibody canakinumab and the IL-1 receptor antagonist anakinra,
have shown to induce a prompt and complete disease remission
[21–25].
MicroRNAs (miRNAs) are small, non-coding RNAs (,18–25
nucleotides in length) that regulate gene expression at a post-
transcriptional level, by degrading mRNA molecules or blocking
their translation [26]. It is now well known that miRNAs can
regulate every aspect of cellular activity, from differentiation and
proliferation to apoptosis and that, as a single miRNA can target
hundreds of mRNAs, aberrant miRNA expression is involved in
the pathogenesis of many diseases [27]. These molecules can be
detected in serum, and their circulating levels have already been
described in inflammatory disorders such as rheumatoid arthritis
and systemic lupus erythematosus [28–30]. To the best of our
knowledge circulating miRNAs in TRAPS, as well as in other
monogenic autoinflammatory disorders have never been investi-
gated.
The aim of our study was to evaluate circulating miRNAs levels
in patients with TRAPS, in comparison to controls without
inflammatory diseases, and to correlate their levels with param-
eters of disease activity and/or disease severity.
Materials and Methods
Patients
Twenty-nine serum samples were obtained from 15 TRAPS
patients (8 males, 7 females) carrying mutations known to be
associated with high disease penetrance (C43R 2/15 pts; C43Y 1/
15 pts; T50M 2/15 pts; C52Y 3/15 pts; C55Y 1/15 pts; S59N 1/
15 pts; S59P 1/15 pts; C88Y 1/15 pts; Del 103–104 1/15 pts;
C114W: 1/15 pts; L167–175del: 1/15 pts). Patients were evalu-
ated between January 2008 and November 2012 at our
institutions. At least one sample was obtained for each patient in
the absence of any treatment. For 6 patients more than one sample
was obtained at different time points in the absence of any
treatment, resulting in a total of 22 samples collected in untreated
individuals. Seven samples were obtained from different patients
during anakinra therapy.
Samples were also obtained from 8 age- and gender-matched
controls without inflammatory diseases (5 males, 3 females) (41
years; range 21–59) attending the outpatient clinic at the
Rheumatology Unit of the University of Siena, for fibromyalgia
and/or carpal tunnel syndrome and who tested negative for
TRAPS mutations. These subjects underwent detailed clinical and
laboratory workup, in order to rule out any inflammatory,
metabolic, and neoplastic disorders (in particular, they all showed
inflammatory markers within normal values). Table 1 summarises
the clinical and demographic characteristics of the samples
collected from treated and untreated TRAPS patients. All patients
and controls were Caucasians of Italian origin. Written informed
consent was obtained both from patients and controls. The study
protocol was reviewed and approved by the University of Siena
Institutional Ethics Committee.
Methods
Data collected in a customized database for each subject with
TRAPS included: i) gender ii) age iii) age at disease onset iv)
disease duration v) duration of fever episodes vi) number of fever
episodes/year (at disease onset) vii) number of fever episodes/year
(during the last year) viii) amyloidosis (presence/absence) ix)
chronic disease course (presence/absence) x) treatment with IL-1
inhibiting drugs (yes/no).
Laboratory Assessment
Blood was taken by venipuncture from patients during routine
follow-up. Laboratory assessment included erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), and SAA. ESR was
measured using the Westergren method (mm/hour), and was
considered normal if ,15 mm/hour for males and ,20 mm/
hour for females. Serum CRP concentrations were measured using
a nephelometric immunoassay (mg/dl); values ,0.5 mg/dl were
considered normal. Serum amyloid A (SAA) levels were measured
by particle-enhanced nephelometry (BNII autoanalyzer, Dade
Behring, Marburg, Germany). Reference value is ,6.4 mg/L.
RNA Extraction
Blood was centrifuged after venipuncture, and serum was
immediately frozen at 280uC until assayed. Total RNA including
microRNAs was extracted from 200 ml of serum using miRNeasy
Table 1. The table summarises clinical and demographic characteristics of TRAPS patients treated with anakinra versus untreated
patients (at the time of sample collection), expressed as median (range) when necessary.
Samples from treated patients (n =7) Samples from untreated patients (n=22)
Age (yrs) 41 (31–52) 42 (19–69)
Disease onset (yrs) 4 (1–26) 4 (1–49)
Nu of fever attacks/year 4 (2–10) 4 (2–10)
Duration of fever attacks (days) 9 (0–10) 10 (0–15)
ESR (mm/h) 5 (5–82) 50 (10–90)
CRP (mg/dl) 0 (0.1–5.14) 5 (0.1–16.1)
SAA (mg/l) 7 (3.5–202) 173 (2–1510)
List of abbreviations: TRAPS, tumor necrosis factor receptor-associated periodic syndrome; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SAA, serum
amyloid A; F, female; M, male; yrs, years; Y, yes; N, no.
doi:10.1371/journal.pone.0073443.t001
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Mini Kit (cat. no. 217004 Qiagen) according to the manufactur-
er’s supplementary protocol with minimal variations. Specifically,
2.5 ml of 5 nM synthetic miRNAs cel-miR-39, cel-miR-54, cel-
miR-238, ebv-miR-BART8, hcmv-miR-UL112, kshv-miR-K12-2
(IDT) were added immediately after QIAzol Lysis Reagent. RNA
Figure 1. Hierarchical cluster representation of miRNAs modulated in TRAPS. Cluster analysis groups samples and genes according to
expression similarity. Genes are in rows, samples in columns. The colors of the genes represented on the heatmap correspond to the values
normalized on miRNA average expression across all samples (see legends); up-regulated miRNAs are in red, down-regulated miRNAs in green. A)
Cluster analysis of miRNAs modulated in TRAPS (blue) vs. controls (red) B) Four miRNAs are differentially expressed in samples from TRAPS patients
during treatment with the interleukin (IL)-1 receptor antagonist anakinra. Treated patients (y) are colored in blue, whereas untreated patients (n) in
red. One treated patient (S22) displays and intermediate expression profile.
doi:10.1371/journal.pone.0073443.g001
Table 2. MiRNAs significantly modulated in TRAPS patients versus controls.
microRNA p (Corr) p Fold change Regulation Chromosome miRBase accession number
hsa-miR-17-5p 0.012103879 4.93E-04 6.7467217 down chr13 MIMAT0000070
hsa-miR-134 0.02169203 0.002648446 16.012423 down chr14 MIMAT0000447
hsa-miR-92a-3p 0.012103879 3.41E-04 22.467995 down chr13 MIMAT0000092
hsa-miR-451a 0.009554302 1.51E-04 81.65974 down chr17 MIMAT0001631
hsa-miR-498 0.009554302 1.67E-04 14.842656 down chr19 MIMAT0002824
hsa-miR-572 0.025193842 0.003376849 9.518456 down chr4 MIMAT0003237
doi:10.1371/journal.pone.0073443.t002
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was eluted in 35 ml and 10 ml were used for microarray
hybridization.
miRNA Expression Profiling
Thirty-seven RNA samples, from 8 controls (8 samples) and 15
TRAPS patients (29 samples), were hybridized on Agilent human
miRNA microarray (#G4470B, Agilent Technologies, Palo Alto,
CA). This chip consists of 15,000 probes, which represent 723
human microRNAs, sourced from the Sanger miRBase database
(Release 10.1). Starting from equal volumes, RNA labeling and
hybridization were performed in accordance to manufacturer’s
indications, as we previously reported [31]. Agilent scanner and
the Feature Extraction 10.5 software (Agilent Technologies) were
used to obtain the microarray raw-data.
Microarray results were analysed using the GeneSpring GX 12
software (Agilent Technologies, Palo Alto, CA). Data transforma-
tion was applied to set all negative raw values at 1.0, followed by
normalization on spiked-in control viral miRNAs (ebv-miR-
BART8, hcmv-miR-UL112, kshv-miR-K12-2). A filter on low
gene expression was used to keep only the probes expressed in at
least one sample. Differentially expressed genes were selected to
have a 1.5-or 2-fold expression difference between groups and a
statistically significant p-value (,0.05), using moderated t-test with
or without Benjamini-Hochberg correction, as indicated in the
text. Differentially expressed genes were employed for Cluster
Analysis of samples using the Manhattan correlation as a measure
of similarity.
Statistical Analysis
Correlation analysis between all miRNAs and clinical variables
was performed using PAM (Prediction Analysis of Microarrays)
software [32]. Statistical analyses were performed using GraphPad
Prism 5 software. Two-tailed Mann-Whitney test was used for
statistical comparisons between groups. Correlations were calcu-
lated using log2 transformed data and Spearman’s correlation
(two-tailed p-value).
Table 3. MiRNAs differentially expressed between treated and untreated TRAPS patients.
microRNA p Fold change Regulation Chromosome mirbase accession
hsa-miR-22-3p 4.79E-05 30.181482 up chr17 MIMAT0000077
hsa-miR-30d-5p 0.003982957 11.236352 up chr8 MIMAT0000245
hsa-miR-92a-3p* 3.88E-06 28.059376 up chr13 MIMAT0000092
hsa-miR-150-3p* 0.017138826 6.3681154 up chr19 MIMAT0004610
*These microRNAs are downregulated in TRAPS patients vs. controls (see Table 2 and Table S2).
doi:10.1371/journal.pone.0073443.t003
Figure 2. Expression of miR-92-3p and miR-150-3p in controls
and in treated and untreated TRAPS patients. The expression
levels of miR-93-3p and miR-150-3p, derived from the microarray
experiment, were plotted in this graph using scatter plot distribution. **
p-value ,0.001 at t-test; * p-value ,0.05 at t-test.
doi:10.1371/journal.pone.0073443.g002
Figure 3. MicroRNAs correlating with clinical and laboratory
features. A) correlation of miR-92b with the number of fever attacks/
year during the 1st year from the index attack of TRAPS. The levels of
miR-92b correlate negatively with the number of fever attacks/year
during the 1st year from the index attack of TRAPS (p 0.0045,
r =20.5589) B) the levels of miR-377-5p are increased in patients
presenting increased serum amyloid A (SAA) levels (p 0.0004, r = 0.66).
doi:10.1371/journal.pone.0073443.g003
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Results
Microarray analysis performed on TRAPS patients and controls
revealed 172 miRNAs whose expression was detectable in at least
1 sample (Table S1). The TRAPS miRNA expression profile was
compared with that of controls, revealing a signature of six
miRNAs specific for TRAPS patients (corrected p-value ,0.05,
Table 2), which were all significantly down-regulated in TRAPS
patients (miR-17-5p, miR-92a-3p, miR-134, miR-451a, miR-498,
miR-572,) and were used for cluster analysis (Figure 1A). The
exclusion of anakinra treated samples increased the number of
differentially expressed miRNAs by two additional units, namely
miR-150-3p and miR-187-5p (Table S2). Figure S1 represents the
hierarchical cluster of untreated TRAPS patients and controls
based on this gene signature.
This signature distinguished between the TRAPS patients and
control group, with only three TRAPS samples (2 samples with
T50M and one with S59P) displaying a profile similar to controls.
To evaluate possible miRNA modulation in TRAPS subgroups,
we examined the effect of treatment with the IL-1 receptor
antagonist anakinra on circulating miRNA profiles, by comparing
treated versus untreated patients. We found 4 miRNAs whose
expression was significantly altered after anakinra treatment (p-
value ,0.05, Table 3).
Figure 1B represents the cluster analysis of TRAPS samples
based on the expression of 4 miRNAs that differentiate treated
from untreated patients. We obtained a very good separation
between the two groups; indeed only one sample was misclassified.
Interestingly, miR-92a-3p and miR-150-3p expression levels
were found to be significantly reduced in untreated TRAPS
patients, while their expression levels were similar to controls in
those patients who were sampled during treatment (Figure 2).
Finally we searched for possible correlations between miRNA
signatures and the clinical and laboratory variables reflecting
disease severity and/or disease activity. MiR-92b levels were
inversely correlated with the number of fever attacks/year during
the 1st year from the index attack of TRAPS (Spearman
r=20.5589) (Figure 3A), while miR-377-5p levels were positively
correlated with SAA circulating levels (Spearman r= 0.66)
(Figure 3B).
Discussion
In recent years, scientific interest in miRNAs has increased
dramatically since they have been shown to play a key role in the
regulation of immunity, including innate and adaptive immune
responses, development, and differentiation of immune cells [33].
Abnormal miRNA expression has also been reported in rheumatic
autoimmune diseases in which it has been observed that miRNAs
can be variably expressed according to disease activity and
progression [30], [34], [35]. Altogether, information available to
date points to miRNAs as potential biomarkers, which could be
exploited to monitor disease activity and response to drugs [35].
MiRNAs themselves are also emerging as potential targets for new
therapeutic strategies. The ultimate goal will be the identification
of a miRNA target or targets that could be manipulated through
specific therapies, aiming at activation or inhibition of specific
miRNAs responsible for the development of disease [28].
Lawrie et al. were among the first to demonstrate the presence
of circulating miRNAs in cell-free body fluids such as plasma and
serum [36]. MiRNAs have been reported as being aberrantly
expressed in blood plasma or serum in different types of disorders
such as cancer, diabetes mellitus and cardiovascular diseases [36–
38]; moreover, changes in circulating miRNAs profiling have
shown potential diagnostic as well as prognostic value in several
disorders [39]. The exact mechanism by which miRNAs enter into
the serum and whether they are biologically functional or simply
biomarkers is still unknown. A recent study reported that miRNAs
could be selectively packaged into micro-vesicles and actively
secreted [40]. To the best of our knowledge no information
concerning circulating miRNAs in TRAPS is available.
Our data show that circulating miRNAs levels are altered in
TRAPS patients versus controls. Six miRNAs were found to be
downregulated in TRAPS (miR-134, miR-17-5p, miR-498, miR-
451a, miR-572, miR-92a-3p) in comparison with controls.
Moreover the expression of 4 additional miRNAs (miR-150-3p,
miR-92a-3p, miR-22-3p, miR-30d-5p) was significantly altered in
untreated patients versus subjects treated with anakinra. It is
worthy of notice that miR-92a-3p and miR-150-3p levels, which
are reduced in untreated TRAPS patients compared with controls,
are restored to levels comparable with controls during anakinra
treatment. In addition, the expression of other specific circulating
miRNAs significantly correlated with both the number of fever
attacks/year at disease onset (miR-92b levels were significantly
reduced), suggesting a relationship with disease severity, and with
enhanced SAA levels (miR-377-5p levels were significantly
enhanced). Among the miRNAs which we found to be altered in
TRAPS, MiR-150, miR-92 and miR-17 have been shown to be
key regulators of specific lineage choices in the adaptive immune
system and serum miR-150 levels have recently been negatively
correlated with the plasma TNF-a levels in patients with sepsis
[41]. Their role in TRAPS still needs to be elucidated.
A growing number of studies have shown that circulating
miRNA expression profiling is of increasing importance as a useful
diagnostic and prognostic tool. In patients with a TRAPS-like
disease, characterized by clinical features consistent with TRAPS
but no mutation in the TNFRSF1A gene [42], circulating miRNA
expression profiling could potentially become useful as a diagnostic
signature, opening the way to a better understanding of the
molecular mechanisms underlying this complex phenotype,
Moreover, our data suggest that serum miRNA levels could be
taken into future consideration for monitoring the response to
treatment in TRAPS patients. Looking a bit further into the
future, a better knowledge about miRNAs role in TRAPS could
also potentially provide novel treatment targets [40], [43–46]. We
acknowledge the limitations of our small samples size, and
therefore a further study involving larger cohorts of patients and
the use of different technical approaches is being planned.
Conclusions
Although further studies are mandatory, serum miRNAs levels
show a baseline pattern in TRAPS and thus deserve further studies
to exploit their potential role as markers of disease and response to
therapeutic intervention.
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